ENDP Endo International plc - Ordina

13.12
+0.23  (2%)
Previous Close 12.89
Open 12.94
Price To book 1.31
Market Cap 2.93B
Shares 223,112,000
Volume 3,907,440
Short Ratio 1.60
Av. Daily Volume 9,105,190

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER no longer outweigh its risks.
OPANA ER
Management of pain
Phase 2 trial did not meet endpoint
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Approved October 26, 2015.
BEMA Buprenorphine
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate
CRL issued May 30 2013. Approved March 6 2014.
AVEED (testosterone undecanoate) intramuscular injection
Men diagnosed with hypogonadism
Phase 2b data released November 17, 2016. Met endpoints. Phase 3 planned for 2H 2017.
XIAFLEX
Edematous fibrosclerotic panniculopathy (“cellulite”)

SEC Filings

  1. 8-K - Current report 17862648
  2. CT ORDER - Confidential treatment order 17860063
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825676
  4. 8-K - Current report 17824364
  5. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17795992
  6. DEF 14A - Other definitive proxy statements 17795887
  7. 8-K - Current report 17791214
  8. 8-K - Current report 17761139
  9. 8-K - Current report 17754829
  10. 8-K - Current report 17751670